This interview is the second of a 2-part series with Dr. Randall Bateman about Alzheimer’s disease clinical trials participation. We discuss how data and samples from the DIAN and DIAN-TU studies accelerate progress worldwide, the importance of continued study participation, brain donation, new tau-targeting drug trials, and more.